Product Description
Tyzivumab is a first-in-class monoclonal antibody designed and engineered to neutralize Zika virus by binding to a specific quaternary epitope of the envelope (E) protein on virus surface. (Sourced from: https://www.tychan.com)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Antibody
Route of Administration: Injection
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Tychan Pte Ltd.
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
![Map of Global Clinical Trials for Tyzivumab](https://pryzm-maps.s3.us-west-2.amazonaws.com/666666current_maps.png)
Countries in Clinic: